Flag of the European Union EU Clinical Trials Register Help

Clinical trials for 2-

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38,669 result(s) found for: 2-. Displaying page 625 of 1,934.
    «« First « Previous 621  622  623  624  625  626  627  628  629  Next» Last»»
    EudraCT Number: 2018-002211-10 Sponsor Protocol Number: GRASPA-TNBC-2018-02 Start Date*: 2019-03-20
    Sponsor Name:ERYTECH Pharma
    Full Title: A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone for the Treatment of Patients with Metastatic or Locally Recurrent T...
    Medical condition: Triple-Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001638-33 Sponsor Protocol Number: IKEM-CEM-01 Start Date*: 2012-10-10
    Sponsor Name:Institute for Clinical and Experimental Medicine
    Full Title: Cholesterol 7alpha-hydroxylase polymorphism as a predictor cholesterolemia responsiveness
    Medical condition: hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020604 Hypercholesterolemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004233-16 Sponsor Protocol Number: CA-209-7HP Start Date*: 2021-05-30
    Sponsor Name:Medical University of Graz
    Full Title: INDUCING REMISSION IN MELANOMA PATIENTS WITH CHECKPOINT INHIBITOR THERAPY USING FECAL MICROBIOTA TRANSPLANTATION.
    Medical condition: Malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001981-40 Sponsor Protocol Number: ICO-N-2013-03 Start Date*: 2013-09-10
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title: Pilot feasibility study of fertility preservation by ovarian stimulation associated with tamoxifen and oocyte or embryo freezing prior chemotherapy for breast cancer.
    Medical condition: Invasive breast cancer in women under 40 years
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002367-29 Sponsor Protocol Number: ITM202203 Start Date*: 2022-09-29
    Sponsor Name:Instituut van Tropische Geneeskunde Antwerpen
    Full Title: A two-centre open-label non-inferiority trial to assess the immunogenicity and safety of an intradermal and an intramuscular single-visit dosing regimen of purified chick-embryo cell-culture rabies...
    Medical condition: Rabies is a viral infection that affects the central nervous system. It causes encephalitis which is almost invariably fatal. Preventive vaccination alone implies no complete protection, but simpli...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037742 Rabies PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003323-30 Sponsor Protocol Number: EORTC-1607-GITCG Start Date*: 2020-01-20
    Sponsor Name:European Organisation for the Research and Treatment of Cancer (EORTC)
    Full Title: Open-label first line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer
    Medical condition: Non-resectable or recurrent/metastatic BTC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004655 Biliary carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004593 Bile duct cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004613 Bile duct neoplasms malignant HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019815 Hepatobiliary neoplasms malignant and unspecified HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-004916-21 Sponsor Protocol Number: EROS Start Date*: 2019-07-02
    Sponsor Name:Karolinska Institute
    Full Title: Early intervention and recovery of sexual function in men and women after treatment of rectal cancer–a randomized controlled study with tadalafil compared to standard care
    Medical condition: sexual/ erectile function in women and men after treatment for rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10013356 Sexual function and fertility disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001849-41 Sponsor Protocol Number: 69HCL17_0706 Start Date*: 2019-09-06
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Efficacité de l’éverolimuS pour le traitement des TrAnsplantés Rénaux présentant un Rejet secondaire à l’activation des NK par le « missing-self » - STARR
    Medical condition: Patients transplantés rénaux devant avoir une biopsie du greffon rénal dans le cadre du suivi habituel
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10038533 Renal transplant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000161-32 Sponsor Protocol Number: CLIN-52120-452 Start Date*: 2021-08-11
    Sponsor Name:Ipsen Pharma
    Full Title: A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with Onabotulinu...
    Medical condition: upper limb spasticity (ULS) of any aetiology (in US and France) or post-stroke ULS (in Canada)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001065-21 Sponsor Protocol Number: ET21-023 Start Date*: 2021-10-12
    Sponsor Name:CENTRE LEON BERARD
    Full Title: PAXIPEM - Multicenter phase II study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC)
    Medical condition: Locally advanced or metastatic papillary cell carcinoma (PRCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002442-20 Sponsor Protocol Number: 2019/2886 Start Date*: 2020-02-15
    Sponsor Name:Gustave Roussy
    Full Title: Study evaluating near infrared imaging coupled with indocyanine green for preoperative control of resection margins in ENT surgery.
    Medical condition: visualization of the resection margins by near infrared fluorescence imaging (in vivo and ex vivo) for patients over 18 years of age with ENT epidermoid cancer treated by open surgery or by robot-a...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002008-19 Sponsor Protocol Number: C4591044 Start Date*: 2024-07-16
    Sponsor Name:BioNTech SE
    Full Title: An Interventional, Randomized, Active-Controlled, Phase 1/2/3 Study to Investigate the Safety, Tolerability, and Immunogenicity of BNT162b RNA-Based Vaccine Candidates in Covid-19 Vaccine–Experienc...
    Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10084510 Coronavirus infections HLT
    23.1 10021881 - Infections and infestations 10084529 2019 novel coronavirus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-004439-22 Sponsor Protocol Number: CHUBX2018/64 Start Date*: 2020-03-12
    Sponsor Name:CHU de Bordeaux
    Full Title: TRAnexamic Acid for Preventing blood loss following a cesarean delivery in women with placenta pREVIA: a multicenter randomised, double blind placebo controlled trial (TRAAPrevia)
    Medical condition: Postpartum hemorrhage, placenta previa, prevention, blood loss, transfusion
    Disease: Version SOC Term Classification Code Term Level
    20.1 10036585 - Pregnancy, puerperium and perinatal conditions 10036417 Postpartum haemorrhage PT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036585 Pregnancy, puerperium and perinatal conditions SOC
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001229-18 Sponsor Protocol Number: FIL_GAUDEALIS Start Date*: 2019-06-13
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Idelalisib (I) in combination with Obinutuzumab (G) for the treatment of patients with relapsed / refractory follicular lymphoma: multicentric phase II single arm study.
    Medical condition: recurrent / refractory follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000311-71 Sponsor Protocol Number: APHP180572 Start Date*: 2022-02-11
    Sponsor Name:AP-HP/DRCD
    Full Title: Pilot study of a new technique of Oral Fecal Transplantation using frozen stool capsules for the maintenance treatment of UC with pediatric onset
    Medical condition: ulcerative colitis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004748-27 Sponsor Protocol Number: EPIDAURUS-2020 Start Date*: 2022-04-21
    Sponsor Name:LMU University Hospital Munich
    Full Title: Escalated single platelet inhibition for one month plus direct oral anticoagulation in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention
    Medical condition: Patients with atrial fibrillation and ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) (biomarker -positive acute coronary syndrome) und...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10028596 Myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000355-40 Sponsor Protocol Number: SOLARIS Start Date*: 2021-09-20
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    Full Title: SOLARIS – A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refractory to atezolizumab and bevacizumab/ IO-based therapy
    Medical condition: advanced stage hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073069 Hepatic cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001277-17 Sponsor Protocol Number: 2017/2536 Start Date*: 2017-12-22
    Sponsor Name:Gustave Roussy
    Full Title: Adjuvant immunotherapy after salvage surgery in head and neck squamous cell carcinoma : phase 2 trial evaluating the efficacy and the toxicity of nivolumab alone, and of the combination nivolumab ...
    Medical condition: high risk recurrent head and neck squamous cell carcinoma (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005332-27 Sponsor Protocol Number: WA43811 Start Date*: 2022-01-31
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE Ib, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB IN PEDIATRIC PATIENTS HOSPITALIZED WITH COVID-19
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Prematurely Ended) GR (Completed) FR (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003765-18 Sponsor Protocol Number: AIFA-TRS-2018-00001238 Start Date*: 2020-03-20
    Sponsor Name:DIPARTIMENTO AD ATTIVITà INTEGRATA CHIRURGICO, MEDICO, ODONTOIATRICO E DI SCIENZE MORFOLOGICHE
    Full Title: Gender-related response to Tyrosine Kinase-Inhibitor drugs in hepatocellular carcinoma
    Medical condition: Patients with advanced hepatocellular carcinoma only eligible for systemic treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 621  622  623  624  625  626  627  628  629  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 26 18:59:59 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA